A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a patient infected with pathogenic organisms; wherein X and Y are each independently selected from C, N, O and S, provided at least one of X and Y is N, O or S; wherein R.sup.1 and R.sup.2 are each independently selected from an optionally substituted C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, aryl, heteroaryl or alkylaryl group; and wherein Z is selected from H, —CN, —NO.sub.2, —NR.sup.3R.sup.4, —NR.sup.5(CO)R.sup.6; C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, —(CO)WR.sup.12, hydroxy, amino, thiol, chloro, fluoro, CF.sub.3, CHF.sub.2 or CH.sub.2F groups. The compounds may be effective in treating patients/animals infected with parasites selected from Schistosoma, Haemonchus, Eimeria, Echinococcus, Dirofilaria, Fasciola or Plasmodium parasites. Additionally or alternatively, the compounds of formula (I) may be effective in treating patients infected with pathogenic bacteria selected from S. aureus, MRSA and Enterococcus faecalis.

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a patient infected with pathogenic organisms; wherein X and Y are each independently selected from C, N, O and S, provided at least one of X and Y is N, O or S; wherein R.sup.1 and R.sup.2 are each independently selected from an optionally substituted C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, aryl, heteroaryl or alkylaryl group; and wherein Z is selected from H, —CN, —NO.sub.2, —NR.sup.3R.sup.4, —NR.sup.5(CO)R.sup.6; C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, —(CO)WR.sup.12, hydroxy, amino, thiol, chloro, fluoro, CF.sub.3, CHF.sub.2 or CH.sub.2F groups. The compounds may be effective in treating patients/animals infected with parasites selected from Schistosoma, Haemonchus, Eimeria, Echinococcus, Dirofilaria, Fasciola or Plasmodium parasites. Additionally or alternatively, the compounds of formula (I) may be effective in treating patients infected with pathogenic bacteria selected from S. aureus, MRSA and Enterococcus faecalis.

Para-acyl substituted diazacyclohexenes, medical formulations thereof and methods for making and using the same.

A compound represented by the following formula (1):

##STR00001##

[wherein R.sup.1 represents a hydrogen atom or a methyl group; R.sup.2 represents an aromatic ring group optionally having a substituent or an alkyl group substituted with an aromatic ring group optionally having a substituent; X.sup.1 represents a (thio)ester bond, a (thio)carbonate bond, a (thio)amide bond, a (thio)urethane bond, a (thio)urea bond, a (thio)ether bond, oxygen, sulfur, or a nitrogen atom optionally having a substituent; X.sup.2 represents oxygen, sulfur, or a nitrogen atom optionally having a substituent; A represents a divalent group optionally having a substituent; L represents an (m+1)-valent linking group optionally having a substituent; m represents an integer of 1 to 3; and n represents 0 or 1].

A compound represented by the following formula (1):

##STR00001##

[wherein R.sup.1 represents a hydrogen atom or a methyl group; R.sup.2 represents an aromatic ring group optionally having a substituent or an alkyl group substituted with an aromatic ring group optionally having a substituent; X.sup.1 represents a (thio)ester bond, a (thio)carbonate bond, a (thio)amide bond, a (thio)urethane bond, a (thio)urea bond, a (thio)ether bond, oxygen, sulfur, or a nitrogen atom optionally having a substituent; X.sup.2 represents oxygen, sulfur, or a nitrogen atom optionally having a substituent; A represents a divalent group optionally having a substituent; L represents an (m+1)-valent linking group optionally having a substituent; m represents an integer of 1 to 3; and n represents 0 or 1].

The invention relates to Pro-drugs, comprising red-ox-sensitive cleavage sites. The compounds may be utilized in medical practice for targeting of si RNA, antisense oligonucleotides or protein-based therapeutics to the cytoplasmatic compartment of cells both in vitro or in vivo, in a subject in need.

The invention relates to Pro-drugs, comprising red-ox-sensitive cleavage sites. The compounds may be utilized in medical practice for targeting of si RNA, antisense oligonucleotides or protein-based therapeutics to the cytoplasmatic compartment of cells both in vitro or in vivo, in a subject in need.

The present disclosure provides a nitrogen-containing compound, an electronic element and an electronic device, which belongs to the technical field of organic materials. The nitrogen-containing compound has a structure of Chemical Formula 1, wherein R.sub.1 and R.sub.2 are each independently selected from hydrogen or a group represented by Chemical Formula 1-1, and one and only one of R.sub.1 and R.sub.2 has the group of Chemical Formula 1-1; when R.sub.1 or R.sub.2 is selected from hydrogen, said R.sub.1 and R.sub.2 may be replaced by R.sub.4. The nitrogen-containing compound can improve the performance of electronic elements.

##STR00001##

The present disclosure provides a nitrogen-containing compound, an electronic element and an electronic device, which belongs to the technical field of organic materials. The nitrogen-containing compound has a structure of Chemical Formula 1, wherein R.sub.1 and R.sub.2 are each independently selected from hydrogen or a group represented by Chemical Formula 1-1, and one and only one of R.sub.1 and R.sub.2 has the group of Chemical Formula 1-1; when R.sub.1 or R.sub.2 is selected from hydrogen, said R.sub.1 and R.sub.2 may be replaced by R.sub.4. The nitrogen-containing compound can improve the performance of electronic elements.

##STR00001##

A resist composition including a compound represented by formula (b1) in which R.sup.b1 represents an aryl group which may have a substituent; R.sup.b2 and R.sup.b3 each independently represents an aryl group which may have a substituent or an alkyl group which may have a substituent; provided that at least one of the aryl group represented by R.sup.b1 and the aryl group or the alkyl group represented by R.sup.b2 or R.sup.b3 has a substituent containing a halogen atom, and at least one of the aryl group represented by R.sup.b1 and the aryl group or the alkyl group represented by R.sup.b2 or R.sup.b3 has a substituent containing a sulfonyl group; and X.sup.− represents a counteranion. ##STR00001##